🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

286 results for “Hoffmann-La Roche” Clear

  1. Vamikibart

    Hoffmann-La Roche

    Uveitic Macular Edema

    phase 3 small molecule completed

    1 trial

  2. Vemurafenib

    Hoffmann-La Roche

    Malignant Melanoma

    phase 3 small molecule completed

    2 trials

  3. Venclexta, Venclyxto, Levact 2,5 mg/ml Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Venclexta, Venclyxto, Fludarabinphosphat "Ebewe", koncentrat til injektions-/infusionsvæske, opløsning, Venclexta, Venclyxto, Fludarabin Ebewe 25 mg/ml injektio-/infuusiokonsentraatti, liuosta varten, Fludarabin Sandoz 25 mg/ml injekčný alebo infúzny koncentrát, MabThera 500 mg concentrate for solution for infusion, Levact 2,5 mg/ml poudre pour solution à diluer pour perfusion, Bendamustin cell pharm® 2,5

    Hoffmann-La Roche

    Chronic Lymphocytic Leukemia (CLL)

    phase 3 small molecule active

    1 trial

  4. Verzenios 150 mg film-coated tablets, Kisqali 200 mg film-coated tablets, Faslodex 250 mg solution for injection., IBRANCE 75 mg film-coated tablets, LEUPRORELIN , Verzenios 100 mg film-coated tablets, RO7197597, RIBOCICLIB, IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, Verzenios 50 mg film-coated tablets

    Hoffmann-La Roche

    Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer

    phase 3 small molecule active

    1 trial

  5. Vincristine placebo, VINCRISTINE , Polivy 140 mg powder for concentrate for solution for infusion., MabThera 500 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Previously Untreated Diffuse large B-cell lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  6. XALKORI 200 mg hard capsules, Alecensa 150 mg hard capsules, XALKORI 200 mg hard capsules, Alectinib (Alecensa), XALKORI 250 mg hard capsules, XALKORI 250 mg hard capsules

    Hoffmann-La Roche

    Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  7. XALKORI 250 mg hard capsules, XALKORI 250 mg hard capsules, XALKORI 200 mg hard capsules, Rozlytrek, Rozlytrek, Rozlytrek, Rozlytrek 100 mg hard capsules, Rozlytrek, Rozlytrek 200 mg hard capsules, Rozlytrek, Rozlytrek, Rozlytrek, Rozlytrek, XALKORI 200 mg hard capsules, Rozlytrek, Rozlytrek

    Hoffmann-La Roche

    Non-small cell lung cancer with ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene rearrangements

    phase 3 small molecule active

    1 trial

  8. erlotinib

    Hoffmann-La Roche

    Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  9. lebrikizumab

    Hoffmann-La Roche

    Asthma

    phase 3 small molecule completed

    2 trials

  10. mycophenolate mofetil (CellCept)

    Hoffmann-La Roche

    Myasthenia Gravis, Generalized

    phase 3 small molecule completed

    1 trial

  11. obinutuzumab

    Hoffmann-La Roche

    Lymphocytic Leukemia, Chronic

    phase 3 small molecule completed

    1 trial

  12. peginterferon alfa-2a

    Hoffmann-La Roche

    Hepatitis C, Chronic

    phase 3 small molecule completed

    2 trials

  13. pioglitazone

    Hoffmann-La Roche

    Diabetes Mellitus Type 2

    phase 3 small molecule completed

    1 trial

  14. tocilizumab [RoActemra/Actemra]

    Hoffmann-La Roche

    Rheumatoid Arthritis

    phase 3 small molecule completed

    3 trials

  15. A 3-Arm, Randomized, Blinded, Active-Controlled, Phase II Study of RO7121661, a PD1-TIM3 Bispecific Antibody and RO7247669, a PD1-LAG3 Bispecific Antibody, Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

    Hoffmann-La Roche

    Advanced or metastatic squamous cell carcinoma of the esophagus

    phase 2 other active

    1 trial

  16. A Phase II Multicenter, Open-Label Study to evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Pediatric Patients with Duchenne Muscular Dystrophy (SHIELD DMD)

    Hoffmann-La Roche

    Duchenne Muscular Dystrophy (DMD)

    phase 2 other active

    1 trial

  17. A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma

    Hoffmann-La Roche

    Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

    phase 2 other active

    1 trial

  18. A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Hoffmann-La Roche

    Previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)

    phase 2 other active

    1 trial

  19. A Phase II, Single-Arm, Open-Label Study Evaluating the Safety and Pharmacokinetics of the Intravenous Fixed‑Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants with Locally Advanced, Recurrent or Metastatic Solid Tumors

    Hoffmann-La Roche

    Solid Tumors

    phase 2 other active

    1 trial

  20. A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis

    Hoffmann-La Roche

    Relapsing Multiple Sclerosis

    phase 2 other active

    1 trial

  21. A Randomized, Open-Label, Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

    Hoffmann-La Roche

    Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

    phase 2 other active

    1 trial

  22. ALECTINIB

    Hoffmann-La Roche

    ALK fusion-positive extracranial solid or primary CNS tumors who have progressed following prior treatment or who have no satisfactory treatment available

    phase 2 small molecule active

    1 trial

  23. Abraxane 5 mg/ml powder for dispersion for infusion., Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung, RoActemra 20 mg/mL concentrate for solution for infusion, Gemcitabin AqVida 38 mg/ml Pulver zur Herstellung einer Infusionslösung, Gemcitabin Kabi 38 mg/ml Pulver zur Herstellung einer Infusionslösung, Avastin 25 mg/ml concentrate for solution for infusion., ATEZOLIZUMAB, Tiragolumab

    Hoffmann-La Roche

    Pancreatic ductal adenocarcinoma (PDAC)

    phase 2 small molecule active

    1 trial

  24. Alogabat

    Hoffmann-La Roche

    Angelman Syndrome

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources